Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Deferred Revenue (2016 - 2024)

Cartesian Therapeutics (RNAC) has disclosed Current Deferred Revenue for 10 consecutive years, with $412000.0 as the latest value for Q1 2024.

  • For Q1 2024, Current Deferred Revenue fell 95.77% year-over-year to $412000.0; the TTM value through Mar 2024 reached $412000.0, down 95.77%, while the annual FY2023 figure was $5.8 million, 886.34% up from the prior year.
  • Current Deferred Revenue hit $412000.0 in Q1 2024 for Cartesian Therapeutics, down from $5.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $115.8 million in Q3 2020 and bottomed at $412000.0 in Q1 2024.
  • Average Current Deferred Revenue over 5 years is $35.1 million, with a median of $9.8 million recorded in 2023.
  • Year-over-year, Current Deferred Revenue surged 11223.46% in 2020 and then tumbled 95.77% in 2024.
  • Cartesian Therapeutics' Current Deferred Revenue stood at $72.0 million in 2020, then plummeted by 87.23% to $9.2 million in 2021, then plummeted by 93.55% to $593000.0 in 2022, then soared by 886.34% to $5.8 million in 2023, then crashed by 92.96% to $412000.0 in 2024.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $412000.0, $5.8 million, and $8.1 million for Q1 2024, Q4 2023, and Q3 2023 respectively.